logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma

< Back

Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma

Drugs

Cancer and Palliative Care

February 2020


Selinexor, in addition to bortezomib and low-dose dexamethasone, is in clinical development for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior therapies. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of red and white blood cells and platelets. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually, the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).

Selinexor is the first in a new family of drugs known as selective inhibition of nuclear export (SINE) compounds that blocks a protein called XPO1. By blocking XPO1, Selinexor blocks the nuclear export of tumour suppressor, growth regulatory, and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. Bortezomib and low-dose dexamethasone are already currently used in progressive MM. If licensed, the addition of Selinexor to bortezomib and low-dose dexamethasone would increase the treatment options for RRMM, a patient group with clear unmet need.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts